(Q31078960)

English

Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: clues for the pathogenesis

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 August 2017

Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: clues for the pathogenesis (English)

1 reference

Europe PubMed Central

12 August 2017

0 references

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

seropositive rheumatoid arthritis

1 reference

based on heuristic

inferred from title

Carlomaurizio Montecucco

14

object named as

Carlomaurizio Montecucco

0 references

object named as

Elisa Gremese

4

0 references

Barbara Tolusso

object named as

Barbara Tolusso

2

0 references

object named as

Alice Mannocci

9

0 references

Gianfranco Ferraccioli

object named as

Gianfranco Ferraccioli

1

0 references

Piercarlo Sarzi-Puttini

object named as

Piercarlo Sarzi-Puttini

12

0 references

8

object named as

Fabiola Atzeni

1 reference

Europe PubMed Central

12 August 2017

10

object named as

Domenico Biasi

1 reference

Europe PubMed Central

12 August 2017

Francesca Bobbio Pallavicini

3

object named as

Francesca Bobbio-Pallavicini

1 reference

Europe PubMed Central

12 August 2017

Maurizio Benucci

6

object named as

Maurizio Benucci

1 reference

Europe PubMed Central

12 August 2017

Mariangela Manfredi

11

object named as

Mariangela Manfredi

1 reference

Europe PubMed Central

12 August 2017

author name string

Viviana Ravagnani

5

1 reference

Europe PubMed Central

12 August 2017

Edoardo Podestà

7

1 reference

Europe PubMed Central

12 August 2017

Bruno Laganà

13

1 reference

Europe PubMed Central

12 August 2017

language of work or name

0 references

publication date

30 July 2012

1 reference

Europe PubMed Central

12 August 2017

1 reference

Europe PubMed Central

12 August 2017

7

1 reference

Europe PubMed Central

12 August 2017

7

1 reference

Europe PubMed Central

12 August 2017

e40362

1 reference

Europe PubMed Central

12 August 2017

copyright license

Creative Commons Attribution 4.0 International

30 July 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408482

21 June 2018

ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408482

21 June 2018

Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408482

21 June 2018

Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408482

21 June 2018

Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408482

21 June 2018

The role of B cells in animal models of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408482

21 June 2018

B cell depletion therapy in rheumatic disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408482

21 June 2018

Therapeutic B cell depletion and regeneration in rheumatoid arthritis: emerging patterns and paradigms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408482

21 June 2018

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408482

21 June 2018

Evolving concepts of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408482

21 June 2018

Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408482

21 June 2018

Do self-perpetuating B lymphocytes drive human autoimmune disease?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408482

21 June 2018

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408482

21 June 2018

Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408482

21 June 2018

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408482

21 June 2018

Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408482

25 November 2018

Clinical and ultrasonographic remission determines different chances of relapse in early and long standing rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408482

25 November 2018

The need for personalised medicine for rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408482

25 November 2018

The changing face of rheumatoid arthritis: sustained remission for all?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408482

25 November 2018

Persistently moderate DAS-28 is not benign: loss of function occurs in early RA despite step-up DMARD therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408482

25 November 2018

Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408482

25 November 2018

Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408482

25 November 2018

Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408482

25 November 2018

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408482

25 November 2018

Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408482

25 November 2018

Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408482

25 November 2018

Induction of tumor necrosis factor alpha production by adhered human monocytes: a key role for Fcgamma receptor type IIIa in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22859946

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse

1 reference

https://pubmed.ncbi.nlm.nih.gov/22859946

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/22859946

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step?

1 reference

https://pubmed.ncbi.nlm.nih.gov/22859946

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22859946

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Synovial tissue heterogeneity in rheumatoid arthritis in relation to disease activity and biomarkers in peripheral blood

1 reference

https://pubmed.ncbi.nlm.nih.gov/22859946

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22859946

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0040362

1 reference

Europe PubMed Central

12 August 2017

2012PLoSO...740362F

0 references

1 reference

Europe PubMed Central

12 August 2017

1 reference

Europe PubMed Central

12 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q31078960&oldid=2049943917"